FDA
approval
· 2023-11-30
FDA Approved: CONTRAVE EXTENDED-RELEASE — Supplemental Application (Nalpropion Pharmaceuticals LLC)
Summary
FDA approved a supplemental application to authorize an extended-release formulation of CONTRAVE (naltrexone hydrochloride and bupropion hydrochloride) for weig…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for CONTRAVE EXTENDED-RELEASE (NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE)